Trial · NCT03809143
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Participant retention | Retention in dosing schedule at 48 weeks | To examine treatment retention at 48 weeks following initiation of monthly depot RBP-6000 buprenorphine injections in patients with opioid dependence transferred from a stable dose of sublingual buprenorphine. |
| Secondary | BUP-XR treatment retention and engagement in ongoing clinical care | 48 weeks | To examine BUP-XR treatment retention and engagement in ongoing clinical care at 48 weeks ortion of participants retained in treatment at 48 weeks following initiation of monthly depot buprenorphine injections and engaged in ongoing clinical care. Treatment retention is defined as remaining on active depot buprenorphine medication AND completing a clinical assessment at 48 weeks. |
| Secondary | Changes in opioid withdrawal | 48 weeks | Change in opioid withdrawal assessed by clinical opioid withdrawal scale (COWS) and subjective opioid withdrawal scale (SOWS) |
| Secondary | Changes in client-reported opioid craving | 48 weeks | Change in client-reported opioid craving assessed by opioid craving scale |
| Secondary | Changes in client-reported drug use | 48 weeks | Change in client-reported use of opioids and other drugs, assessed by the Australian Treatment Outcomes Profile (ATOP) instrument |
| Secondary | BUP-XR dosing schedule adherence | 48 weeks | To evaluate client utilisation of buprenorphine medication during the study, including BUP-XR dose variation, adherence with dosing schedule, and dose supplementation |
| Secondary | BUP-XR safety and tolerability | 48 weeks | To evaluate treatment safety and tolerability by monitoring adverse events, and events of clinical interest such as drug-drug interactions and pain management in clients treated with BUP-XR |
| Secondary | Changes in client-report pain and enjoyment | 48 weeks | To describe client-reported changes to pain and enjoyment of life, assessed by the Pain, Enjoyment, General Activity (PEG) scale |
| Secondary | Demographic factors associated with treatment retention | 48 weeks | To evaluate demographic factors (gender, age, education) associated with treatment retention, assessed by demographic questionnaire |
| Secondary | Client treatment satisfaction score | 48 weeks | Client-reported treatment satisfaction assessed by the Treatment Questionnaire for Medication Satisfaction (TQSM) |
| Secondary | BUP-XR treatment costs | 48 weeks | Costs to services delivering BUP-XR assessed by site-reported expenses and time and motion study |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03809143/registered